AI
ONCE

ArchPoint Investors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

ArchPoint Investors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-400
Closed -$21K – 168
2017
Q4 		$21K Buy
+400
New +$28.7K 0.01% 141

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

ArchPoint Investors's ONCE Position: Q1 2018 in Review

ArchPoint Investors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2018, closing a stake of 400 shares — an estimated $21K sold.

ArchPoint Investors first reported a position in ONCE in Q4 2017 and held it in 1 quarter. The position peaked at $21K in Q4 2017. 162 funds tracked by Wall St. Rank hold ONCE as of Q1 2018.

  • ArchPoint Investors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • ArchPoint Investors sold 400 Spark Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $21K.
  • ArchPoint Investors first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • ArchPoint Investors's Spark Therapeutics, Inc. Common Stock position peaked at $21K in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2018.

Based on ArchPoint Investors's 13F filing for Q1 2018, filed 14 May 2018.